Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/40382
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Pugliatti, M | - |
dc.contributor.author | Hartung, HP | - |
dc.contributor.author | Oreja-Guevara, C | - |
dc.contributor.author | Pozzilli, C | - |
dc.contributor.author | Airas, L | - |
dc.contributor.author | Alkhawajah, M | - |
dc.contributor.author | Grigoriadis, N | - |
dc.contributor.author | Magyari, M | - |
dc.contributor.author | VAN WIJMEERSCH, Bart | - |
dc.contributor.author | Zakaria, M | - |
dc.contributor.author | Linker, R | - |
dc.contributor.author | Chan, A | - |
dc.contributor.author | Vermersch, P | - |
dc.contributor.author | Berger, T | - |
dc.date.accessioned | 2023-06-13T15:31:05Z | - |
dc.date.available | 2023-06-13T15:31:05Z | - |
dc.date.issued | 2022 | - |
dc.date.submitted | 2023-06-06T09:06:37Z | - |
dc.identifier.citation | Frontiers in Immunology, 13 (Art N° 1045101) | - |
dc.identifier.uri | http://hdl.handle.net/1942/40382 | - |
dc.description.abstract | It has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered. | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | vaccines | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | multiple sclerosis | - |
dc.subject.other | disease modifying therapies | - |
dc.subject.other | immune response | - |
dc.subject.other | adverse events | - |
dc.title | Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in | - |
dc.type | Journal Contribution | - |
dc.identifier.volume | 13 | - |
local.bibliographicCitation.jcat | A1 | - |
local.publisher.place | AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND | - |
local.type.refereed | Refereed | - |
local.type.specified | Review | - |
local.bibliographicCitation.artnr | 1045101 | - |
dc.identifier.doi | 10.3389/fimmu.2022.1045101 | - |
dc.identifier.isi | 000891688600001 | - |
local.provider.type | Web of Science | - |
local.uhasselt.international | yes | - |
item.validation | ecoom 2023 | - |
item.fullcitation | Pugliatti, M; Hartung, HP; Oreja-Guevara, C; Pozzilli, C; Airas, L; Alkhawajah, M; Grigoriadis, N; Magyari, M; VAN WIJMEERSCH, Bart; Zakaria, M; Linker, R; Chan, A; Vermersch, P & Berger, T (2022) Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. In: Frontiers in Immunology, 13 (Art N° 1045101). | - |
item.contributor | Pugliatti, M | - |
item.contributor | Hartung, HP | - |
item.contributor | Oreja-Guevara, C | - |
item.contributor | Pozzilli, C | - |
item.contributor | Airas, L | - |
item.contributor | Alkhawajah, M | - |
item.contributor | Grigoriadis, N | - |
item.contributor | Magyari, M | - |
item.contributor | VAN WIJMEERSCH, Bart | - |
item.contributor | Zakaria, M | - |
item.contributor | Linker, R | - |
item.contributor | Chan, A | - |
item.contributor | Vermersch, P | - |
item.contributor | Berger, T | - |
item.accessRights | Open Access | - |
item.fulltext | With Fulltext | - |
crisitem.journal.issn | 1664-3224 | - |
crisitem.journal.eissn | 1664-3224 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-13-1045101.pdf | Published version | 635.75 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.